Capital Market Strategies LLC Sells 79 Shares of Danaher Co. (NYSE:DHR)

Capital Market Strategies LLC lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 7.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 981 shares of the conglomerate’s stock after selling 79 shares during the quarter. Capital Market Strategies LLC’s holdings in Danaher were worth $273,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cetera Advisor Networks LLC lifted its stake in Danaher by 1.9% in the fourth quarter. Cetera Advisor Networks LLC now owns 68,188 shares of the conglomerate’s stock worth $15,775,000 after purchasing an additional 1,256 shares during the last quarter. Pinebridge Investments L.P. lifted its stake in shares of Danaher by 29.7% during the 4th quarter. Pinebridge Investments L.P. now owns 48,664 shares of the conglomerate’s stock worth $11,260,000 after acquiring an additional 11,141 shares during the last quarter. Exencial Wealth Advisors LLC grew its position in Danaher by 0.9% in the 4th quarter. Exencial Wealth Advisors LLC now owns 14,743 shares of the conglomerate’s stock valued at $3,411,000 after acquiring an additional 128 shares during the last quarter. Stephens Inc. AR grew its position in Danaher by 1.0% in the 4th quarter. Stephens Inc. AR now owns 13,601 shares of the conglomerate’s stock valued at $3,147,000 after acquiring an additional 139 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Danaher by 5.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 1,019,434 shares of the conglomerate’s stock valued at $235,836,000 after acquiring an additional 55,458 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the company. Robert W. Baird upped their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Barclays raised their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Danaher Stock Performance

Shares of DHR stock opened at $270.68 on Friday. The business’s fifty day simple moving average is $271.15 and its 200-day simple moving average is $258.43. The company has a market cap of $200.49 billion, a PE ratio of 45.88, a PEG ratio of 4.55 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 earnings per share. Analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.